Avid Bioservices Inc (CDMO)

[bfiest]

Some interesting industry facts and projections that effects Avid’s potential.

“But the last two years have seen venture capital and overall funding within the industry dry up due to the economic downturn, which has heavily impacted many biotech companies.”

“Although the biotech IPO slump continued through the first half of 2023, there are promising signs of recovery in the industry. While investors have become more cautious, they appear increasingly interested in later-stage biotech companies with compelling clinical trial results.”

“Sees brighter times for biotech

In the coming 12 to 18 months, the investment company expects the majority of biotech companies to recover from the low levels prevailing at the moment.”


“Inside the market of emerging biotech’s

In its latest quarterly report, IPO research firm Renaissance Capital said it expects a “steady rise in listings” in the second half of 2023, citing a pause in interest rate hikes and improving returns among this year's debuting companies.”

This too will pass.